Biomarkers of Parkinson's disease: recent insights, current challenges, and future prospects

References

• Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001;69:89–95.
   PubMed Web of Science ®Google Scholar
• Wright-Willis A, Evanoff BA, Lian M, Criswell SR, Racette BA. Geographic and ethnic variation in Parkinson disease: a population-based study of US Medicare beneficiaries. Neuroepidemiology. 2010;34(3):143–151.
   Web of Science ®Google Scholar
• Pont-Sunyer C, Hotter A, Gaig C, et al. The onset of nonmotor symptoms in Parkinson’s disease (the ONSET PD study). Mov Disord. 2015;30(2):229–237.
   PubMed Web of Science ®Google Scholar
• Noyce AJ, Bestwick JP, Silveira-Moriyama L, et al. Meta-analysis of early nonmotor features and risk factors for Parkinson disease. Ann Neurol. 2012;72(6):893–901.
   PubMed Web of Science ®Google Scholar
• Moccia M, Erro R, Picillo M, et al. Quitting smoking: an early non-motor feature of Parkinson’s disease? Parkinsonism Relat Disord. 2015;21(3):216–220.
   Web of Science ®Google Scholar
• Schrag A, Horsfall L, Walters K, Noyce A, Petersen I. Prediagnostic presentations of Parkinson’s disease in primary care: a case-control study. Lancet Neurol. 2015;14(1):57–64.
   PubMed Web of Science ®Google Scholar
• Wu YH, Liao YC, Chen YH, Chang MH, Lin CH. Risk of premotor symptoms in patients with newly diagnosed PD: a nationwide, population-based, case-control study in Taiwan. PLoS One. 2015; 10(6):e0130282.
   Web of Science ®Google Scholar
• Shen CC, Tsai SJ, Perng CL, Kuo BI, Yang AC. Risk of Parkinson disease after depression: a nationwide population-based study. Neurology. 2013;81(17):1538–1544.
   Web of Science ®Google Scholar
• Adams-Carr KL, Bestwick JP, Shribman S, Lees A, Schrag A, Noyce AJ. Constipation preceding Parkinson’s disease: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry. Epub 2015 Sep 7.
   Google Scholar
• Schenck CH, Boeve BF, Mahowald MW. Delayed emergence of a parkinsonian disorder or dementia in 81% of older males initially diagnosed with idiopathic REM sleep behavior disorder: 16-year update on a previously reported series. Sleep Med. 2013;14(8):744–748.
   PubMed Web of Science ®Google Scholar
• Iranzo A, Tolosa E, Gelpi E, Molinuevo JL, Valldeoriola F, Serradell M, et al. Neurodegenerative disease status and post-mortem pathology in idiopathic rapid-eye-movement sleep behaviour disorder: an observational cohort study. Lancet Neurol. 2013;12(5):443–453.
   PubMed Web of Science ®Google Scholar
• Berg D, Marek K, Ross GW, Poewe W. Defining at-risk populations for Parkinson’s disease: lessons from ongoing studies. Mov Disord. 2012;27(5):656–665.
   PubMed Web of Science ®Google Scholar
• O’Sullivan SS, Williams DR, Gallagher DA, Massey LA, Silveira-Moriyama L, Lees AJ. Nonmotor symptoms as presenting complaints in Parkinson’s disease: a clinicopathological study. Mov Disord. 2008;23(1):101–106.
   PubMed Web of Science ®Google Scholar
• Hu G. Total cholesterol and the risk of Parkinson’s disease: a review for some new findings. Parkinsons Dis. 2010;2010:836962.
   Web of Science ®Google Scholar
• De Lau LML, Koudstaal PJ, Hofman A, Breteler MMB. Serum cholesterol levels and the risk of Parkinson’s disease. Am J Epidemiol. 2006;164(10):998–1002.
   PubMed Web of Science ®Google Scholar
• Godau J, Herfurth M, Kattner B, Gasser T, Berg D. Increased serum insulin-like growth factor 1 in early idiopathic Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2010;81(5):536–538.
   Web of Science ®Google Scholar
• Godau J, Knauel K, Weber K, et al. Serum insulinlike growth factor 1 as possible marker for risk and early diagnosis of Parkinson disease. Arch Neurol. 2011;68(7):925–931.
   Google Scholar
• Knekt P, Kilkkinen A, Rissanen H, Marniemi J, Sääksjärvi K, Heliövaara M. Serum vitamin D and the risk of Parkinson disease. Arch Neurol. 2010;67(7):808–811.
   PubMedGoogle Scholar
• de Lau L, Koudstaal P, Hofman A, Breteler M. Serum uric acid levels and the risk of Parkinson disease. Ann Neurol. 2005;585:797–800.
   Google Scholar
• Weisskopf M, O’Reilly E, Chen H, Schwarzschild M, Ascherio A. Plasma urate and risk of Parkinson’s disease. Am J Epidemiol. 2007;166(5):561–567.
   PubMed Web of Science ®Google Scholar
• Chen H, Mosley T, Alonso A, Huang X. Plasma urate and Parkinson’s disease in the Atherosclerosis Risk in Communities (ARIC) study. Am J Epidemiol. 2009;169(9):1064–1069.
   Web of Science ®Google Scholar
• Alonso A, Rodríguez L, Logroscino G, Hernán M. Gout and risk of Parkinson disease: a prospective study. Neurology. 2007;69(17):1696–1700.
   Web of Science ®Google Scholar
• De Vera M, Rahman M, Rankin J, Kopec J, Gao X, Choi H. Gout and the risk of Parkinson’s disease: a cohort study. Arthritis Rheum. 2008;59(11):1549–1554.
   Google Scholar
• Stern MB, Siderowf A. Parkinson’s at risk syndrome: can Parkinson’s disease be predicted? Mov Disord. 2010;25 Suppl 1:S89–93.
   Google Scholar
• Siderowf A, Jennings D, Eberly S, et al. Impaired olfaction and other prodromal features in the Parkinson at-risk syndrome study. Mov Disord. 2012;27(3):406–412.
   PubMed Web of Science ®Google Scholar
• Jennings D, Siderowf A, Stern M, et al. Imaging prodromal Parkinson disease: the Parkinson associated risk syndrome study. Neurology. 2014;83(19):1739–1746.
   PubMed Web of Science ®Google Scholar
• Berg D, Seppi K, Behnke S, et al. Enlarged substantia nigra hyperechogenicity and risk for Parkinson disease: a 37-month 3-center study of 1847 older persons. Arch Neurol. 2011;68(7):932–937.
   PubMed Web of Science ®Google Scholar
• Berg D, Behnke S, Seppi K, et al. Enlarged hyperechogenic substantia nigra as a risk marker for Parkinson’s disease. Mov Disord. 2013;28(2):216–219.
   Web of Science ®Google Scholar
• Iranzo A, Stockner H, Serradell M, et al. Five-year follow-up of substantia nigra echogenicity in idiopathic REM sleep behavior disorder. Mov Disord. 2014;29(14):1774–1780.
   Web of Science ®Google Scholar
• Iranzo A, Valldeoriola F, Lomeña F, et al. Serial dopamine transporter imaging of nigrostriatal function in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study. Lancet Neurol. 2011;10(9):797–805.
   PubMed Web of Science ®Google Scholar
• Vilas D, Ispierto L, Álvarez R, et al. Clinical and imaging markers in premotor LRRK2 G2019S mutation carriers. Parkinsonism Relat Disord. 2015;21(10):1170–1176.
   Web of Science ®Google Scholar
• Helmich RC, Thaler A, van Nuenen BF, et al. Reorganization of corticostriatal circuits in healthy G2019S LRRK2 carriers. Neurology. 2015;84(4):399–406.
   Web of Science ®Google Scholar
• Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinic-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992;55:181–184.
   PubMed Web of Science ®Google Scholar
• Barone P, Antonini A, Colosimo C, et al. The PRIAMO study: a multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson’s disease. Mov Disord. 2009;24(11):1641–1649.
   PubMed Web of Science ®Google Scholar
• Erro R, Santangelo G, Picillo M, et al. Link between non-motor symptoms and cognitive dysfunctions in de novo, drug-naive PD patients. J Neurol. 2012;259(9):1808–1813.
   Web of Science ®Google Scholar
• Picillo M, Amboni M, Erro R, et al. Gender differences in non-motor symptoms in early, drug naïve Parkinson’s disease. J Neurol. 2013;260(11):2849–2855.
   Web of Science ®Google Scholar
• Lewis SJG, Foltynie T, Blackwell AD, Robbins TW, Owen AM, Barker RA. Heterogeneity of Parkinson’s disease in the early clinical stages using a data driven approach. J Neurol Neurosurg Psychiatry. 2005;76(3):343–348.
   PubMed Web of Science ®Google Scholar
• Marras C, Lang A. Parkinson’s disease subtypes: lost in translation? J Neurol Neurosurg Psychiatry. 2013;84(4):409–415.
   Web of Science ®Google Scholar
• Erro R, Vitale C, Amboni M, et al. The heterogeneity of early Parkinson’s disease: a cluster analysis on newly diagnosed untreated patients. PLoS One. 2013;8(8):e70244.
   PubMed Web of Science ®Google Scholar
• Nalls MA, McLean CY, Rick J, et al. Parkinson’s Disease Biomarkers Program and Parkinson’s Progression Marker Initiative investigators. Diagnosis of Parkinson’s disease on the basis of clinical and genetic classification: a population-based modelling study. Lancet Neurol. 2015;14(10):1002–1009.
   Google Scholar
• Köllensperger M, Geser F, Seppi K, et al. European MSA Study Group. Red flags for multiple system atrophy. Mov Disord. 2008; 23(8):1093–1099.
   Web of Science ®Google Scholar
• Todorović Z, Džoljić E, Novaković I, et al. Homocysteine serum levels and MTHFR C677T genotype in patients with Parkinson’s disease, with and without levodopa therapy. J Neurol Sci. 2006;248(1–2):56–61.
   Web of Science ®Google Scholar
• Levin J, Bötzel K, Giese A, Vogeser M, Lorenzl S. Elevated levels of methylmalonate and homocysteine in Parkinson’s disease, progressive supranuclear palsy and amyotrophic lateral sclerosis. Dement Geriatr Cogn Disord. 2010;29:553–559.
   PubMed Web of Science ®Google Scholar
• Chen W, Cheng X, Zhang X, Zhang Q, Sun H. The expression features of serum Cystatin C and homocysteine of Parkinson’s disease with mild cognitive dysfunction. Eur Rev Med Pharmacol Sci. 2015;19:2957–2963.
   PubMed Web of Science ®Google Scholar
• Scalzo P, Kümmer A, Bretas TL, Cardoso F, Teixeira AL. Serum levels of brain-derived neurotrophic factor correlate with motor impairment in Parkinson’s disease. J Neurol. 2010;257(4):540–545.
   PubMed Web of Science ®Google Scholar
• Ziebell M, Khalid U, Klein AB, et al. Striatal dopamine transporter binding correlates with serum BDNF levels in patients with striatal dopaminergic neurodegeneration. Neurobiol Aging. 2012;33(2):428.e1–5.
   Web of Science ®Google Scholar
• Pellecchia MT, Pivonello R, Salvatore E, et al. Growth hormone response to arginine test distinguishes multiple system atrophy from Parkinson’s disease and idiopathic late-onset cerebellar ataxia. Clin Endocrinol (Oxf). 2005;62(4):428–433.
   Web of Science ®Google Scholar
• Picillo M, Erro R, Santangelo G, et al. Insulin-like growth factor-1 and progression of motor symptoms in early, drug-naïve Parkinson’s disease. J Neurol. 2013;260(7):1724–1730.
   Web of Science ®Google Scholar
• Pellecchia MT, Santangelo G, Picillo M, et al. Insulin-like growth factor-1 predicts cognitive functions at 2-year follow-up in early, drug-naïve Parkinson’s disease. Eur J Neurol. 2014;21(5):802–807.
   Web of Science ®Google Scholar
• Liu Y, Zhang B-S. Serum 25-hydroxyvitamin D predicts severity in Parkinson’s disease patients. Neurol Sci. 2014;35(1):67–71.
   PubMed Web of Science ®Google Scholar
• Palladino R, Moccia M, De Pascale T, et al. Season of birth and Parkinson’s disease: possible relationship? Neurol Sci. 2015;36(8):1457–1462.
   Web of Science ®Google Scholar
• Gardener H, Gao X, Chen H, Schwarzschild MA, Spiegelman D, Ascherio A. Prenatal and early life factors and risk of Parkinson’s disease. Mov Disord. 2010;25(11):1560–1567.
   Web of Science ®Google Scholar
• Mahlknecht P, Stemberger S, Sprenger F, et al. An antibody microarray analysis of serum cytokines in neurodegenerative Parkinsonian syndromes. Proteome Sci. 2012;10(1):71.
   PubMed Web of Science ®Google Scholar
• Moccia M, Picillo M, Erro R, et al. Increased bilirubin levels in de novo Parkinson’s disease. Eur J Neurol. 2015;22(6):954–959.
   PubMed Web of Science ®Google Scholar
• Hatano T, Saiki S, Okuzumi A, Mohney R, Hattori N. Identification of novel biomarkers for Parkinson’s disease by metabolomic technologies. J Neurol Neurosurg Psychiatry. Epub 2015 Mar 20.
   Google Scholar
• Bharucha KJ, Friedman JK, Vincent AS, Ross ED. Lower serum ceruloplasmin levels correlate with younger age of onset in Parkinson’s disease. J Neurol. 2008;255(12):1957–1962.
   Web of Science ®Google Scholar
• Jin L, Wang J, Zhao L, et al. Decreased serum ceruloplasmin levels characteristically aggravate nigral iron deposition in Parkinson’s disease. Brain. 2011;134(1):50–58.
   Google Scholar
• Shen C, Guo Y, Luo W, Lin C, Ding M. Serum urate and the risk of Parkinson’s disease: results from a meta-analysis. Can J Neurol Sci. 2012;(88):73–79.
   Google Scholar
• Shen L, Ji H-F. Low uric acid levels in patients with Parkinson’s disease: evidence from meta-analysis. BMJ. 2013;3(11):e003620.
   Web of Science ®Google Scholar
• Schwarzschild MA, Marek K, Eberly S, et al. Serum urate and probability of dopaminergic deficit in early “Parkinson’s disease”. Mov Disord. 2011;26(10):1864–1868.
   Web of Science ®Google Scholar
• Moccia M, Pappatà S, Erro R, et al. Uric acid relates to dopamine transporter availability in Parkinson’s disease. Acta Neurol Scand. 2015a;123(2):127–131.
   Google Scholar
• Mariani S, Ventriglia M, Simonelli I, et al. Association between sex, systemic iron variation and probability of Parkinson’s disease. Int J Neurosci. 2015;126(4):354–360.
   Web of Science ®Google Scholar
• Fukushima T, Tan X, Luo Y, Kanda H. Relationship between blood levels of heavy metals and Parkinson’s disease in China. Neuroepidemiology. 2010;34(1):18–24.
   PubMed Web of Science ®Google Scholar
• Simonsen A, Kuiperij B, Ali El-Agnaf O, et al. The utility of α-synuclein as biofluid marker in neurodegenerative diseases: a systematic review of the literature. Biomark Med. Epub 2015 Aug 28.
   Google Scholar
• Williams SM, Schulz P, Sierks MR. Oligomeric α-synuclein and β-amyloid variants as potential biomarkers for Parkinson’s and Alzheimer’s diseases. Eur J Neurosci. Epub 2015 Aug 31.
   Google Scholar
• Gupta V, Garg RK, Khattri S. Serological Analysis of Alpha-synuclein and NF-κB in Parkinson’s Disease Patients. J Clin Diagn Res. 2015;9(5):BC01–04.
   Google Scholar
• Shi M, Liu C, Cook TJ et al. Plasma exosomal α-synuclein is likely CNS-derived and increased in Parkinson’s disease. Acta Neuropathol. 2014;128(5):639–650.
   PubMed Web of Science ®Google Scholar
• Alves G, Pedersen KF, Bloem BR, et al. Cerebrospinal fluid amyloid-β and phenotypic heterogeneity in de novo Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2013;84:537–543.
   PubMed Web of Science ®Google Scholar
• Stav AL, Aarsland D, Johansen KK, Hessen E, Auning E, Fladby T. Amyloid-β and α-synuclein cerebrospinal fluid biomarkers and cognition in early Parkinson’s disease. Parkinsonism Relat Disord. 2015;21:758–764.
   PubMed Web of Science ®Google Scholar
• Bibl M, Mollenhauer B, Esselmann H, et al. CSF amyloid-β-peptides in Alzheimer’s disease, dementia with Lewy bodies and Parkinson’s disease dementia. Brain. 2006;129:1177–1187.
   PubMed Web of Science ®Google Scholar
• van Dijk KD, Teunissen CE, Drukarch B, et al. Diagnostic cerebrospinal fluid biomarkers for Parkinson’s disease: a pathogenetically based approach. Neurobiol Dis. 2010;39:229–241.
   PubMed Web of Science ®Google Scholar
• Jiménez-Jiménez FJ, Alonso-Navarro H, García-Martín E, Agúndez JAG. Cerebrospinal fluid biochemical studies in patients with Parkinson’s disease: toward a potential search for biomarkers for this disease. Front Cell Neurosci. 2014;11:369.
   Google Scholar
• Wennström M, Surova Y, Hall S, et al. Low CSF levels of both α-synuclein and the α-synuclein cleaving enzyme neurosin in patients with synucleinopathy. PLoS One. 2013;8:e53250.
   PubMed Web of Science ®Google Scholar
• Přikrylová Vranová H, Mareš J, Nevrlý M, et al. CSF markers of neurodegeneration in Parkinson’s disease. J Neural Transm. 2010;117:1177–1181.
   PubMed Web of Science ®Google Scholar
• Waragai M, Wei J, Fujita M, et al. Increased level of DJ-1 in the cerebrospinal fluids of sporadic Parkinson’s disease. Biochem Biophys Res Commun. 2006;345:967–972.
   PubMed Web of Science ®Google Scholar
• Herbert MK, Eeftens JM, Aerts MB, et al. CSF levels of DJ-1 and tau distinguish MSA patients from PD patients and controls. Parkinsonism Relat Disord. 2014;20:112–115.
   PubMed Web of Science ®Google Scholar
• Kikuchi A, Takeda A, Onodera H, et al. Systemic increase of oxidative nucleic acid damage in Parkinson’s disease and multiple system atrophy. Neurobiol Dis. 2002;9:244–248.
   PubMed Web of Science ®Google Scholar
• Buhmann C, Arlt S, Kontush A, et al. Plasma and CSF markers of oxidative stress are increased in Parkinson’s disease and influenced by antiparkinsonian medication. Neurobiol Dis. 2004;15:160–170.
   PubMed Web of Science ®Google Scholar
• Öhman A, Forsgren L. NMR metabonomics of cerebrospinal fluid distinguishes between Parkinson’s disease and controls. Neurosci Lett. 2015;594:36–39.
   Web of Science ®Google Scholar
• Trupp M, Jonsson P, Ohrfelt A, et al. Metabolite and peptide levels in plasma and CSF differentiating healthy controls from patients with newly diagnosed Parkinson’s disease. J Parkinsons Dis. 2014;4(3):549–560.
   PubMedGoogle Scholar
• Bajaj N, Hauser RA, Grachev ID. Clinical utility of dopamine transporter single photon emission CT (DaT-SPECT) with (123I) ioflupane in diagnosis of parkinsonian syndromes. J Neurol Neurosurg Psychiatry. 2013;84(11):1288–1295.
   PubMed Web of Science ®Google Scholar
• Niethammer M, Eidelberg D. Metabolic brain networks in translational neurology: concepts and applications. Ann Neurol. 2012;72(5):635–647.
   Web of Science ®Google Scholar
• Chung EJ, Lee WY, Yoon WT, Kim BJ, Lee GH. Scintigraphy for differentiating Parkinson’s disease with autonomic dysfunction from Parkinsonism-predominant multiple system atrophy. Mov Disord. 2009;24(11):1650–1655.
   PubMed Web of Science ®Google Scholar
• Reimão S, Pita Lobo P, Neutel D, et al. Substantia nigra neuromelanin magnetic resonance imaging in de novo Parkinson’s disease patients. Eur J Neurol. 2015;22(3):540–546.
   PubMed Web of Science ®Google Scholar
• Zhang D, Liu X, Chen J, Liu B. Distinguishing patients with Parkinson’s disease subtypes from normal controls based on functional network regional efficiencies. PLoS One. 2014;9(12):e115131.
   Web of Science ®Google Scholar
• Bunzeck N, Singh-Curry V, Eckart C, et al. Motor phenotype and magnetic resonance measures of basal ganglia iron levels in Parkinson’s disease. Parkinsonism Relat Disord. 2013;19(12):1136–1142.
   Web of Science ®Google Scholar
• Moccia M, Pappatà S, Picillo M, et al. Dopamine transporter availability in motor subtypes of de novo drug-naïve Parkinson’s disease. J Neurol. 2014;261(11):2112–2118.
   Web of Science ®Google Scholar
• Pellecchia MT, Picillo M, Santangelo G, et al. Cognitive performances and DAT imaging in early Parkinson’s disease with mild cognitive impairment: a preliminary study. Acta Neurol Scand. 2015;131(5):275–281.
   PubMed Web of Science ®Google Scholar
• Erro R, Pappatà S, Amboni M, et al. Anxiety is associated with striatal dopamine transporter availability in newly diagnosed untreated Parkinson’s disease patients. Parkinsonism Relat Disord. 2012;18(9):1034–1038.
   PubMed Web of Science ®Google Scholar
• Rajput AH, Sitte HH, Rajput A, Fenton ME, Pifl C, Hornykiewicz O. Globus pallidus dopamine and Parkinson motor subtypes: clinical and brain biochemical correlation. Neurology. 2008;70(16 Pt 2):1403–1410.
   PubMed Web of Science ®Google Scholar
• Burn DJ, Rowan EN, Allan LM, Molloy S, O’Brien JT, McKeith IG. Motor subtype and cognitive decline in Parkinson’s disease, Parkinson’s disease with dementia, and dementia with Lewy bodies. J Neurol Neurosurg Psychiatry. 2006;77(5):585–589.
   PubMed Web of Science ®Google Scholar
• Picillo M, Amboni M, Erro R, et al. Segmental progression of cardinal motor symptoms in Parkinson’s disease: a pilot study suggesting a practical approach to rate disease course in the early stages. Parkinsonism Relat Disord. 2013;19(12):1143–1148.
   Web of Science ®Google Scholar
• Amboni M, Barone P, Picillo M, et al. A two-year follow-up study of executive dysfunctions in parkinsonian patients with freezing of gait at on-state. Mov Disord. 2010;25(6):800–802.
   Web of Science ®Google Scholar
• Amboni M, Cozzolino A, Longo K, Picillo M, Barone P. Freezing of gait and executive functions in patients with Parkinson’s disease. Mov Disord. 2008;23(3):395–400.
   PubMed Web of Science ®Google Scholar
• Amboni M, Barone P, Iuppariello L, et al. Gait patterns in Parkinsonian patients with or without mild cognitive impairment. Mov Disord. 2012;27(12):1536–1543.
   Web of Science ®Google Scholar
• Picillo M, Dubbioso R, Iodice R, et al. Short-latency afferent inhibition in patients with Parkinson’s disease and freezing of gait. J Neural Transm. 2015;122(11):1533–1540.
   Web of Science ®Google Scholar
• Erro R, Picillo M, Vitale C, et al. Non-motor symptoms in early Parkinson’s disease: a 2-year follow-up study on previously untreated patients. J Neurol Neurosurg Psychiatry. 2013;84(1):14–17.
   Web of Science ®Google Scholar
• Picillo M, Erro R, Amboni M et al. Gender differences in non-motor symptoms in early Parkinson’s disease: a 2-years follow-up study on previously untreated patients. Parkinsonism Relat Disord. 2014;20(8):850–854.
   Web of Science ®Google Scholar
• Santangelo G, Vitale C, Picillo M, et al. Mild Cognitive Impairment in newly diagnosed Parkinson’s disease: A longitudinal prospective study. Parkinsonism Relat Disord. 2015;21(10):1219–1226.
   PubMed Web of Science ®Google Scholar
• Picillo M, Barone P, Pellecchia MT, et al. Evolution of mild cognitive impairment in Parkinson disease. Neurology. 2014;82(15):1384.
   Google Scholar
• Santangelo G, Vitale C, Trojano L, et al. Relationship between apathy and cognitive dysfunctions in de novo untreated Parkinson’s disease: a prospective longitudinal study. Eur J Neurol. 2015;22(2):253–260.
   PubMed Web of Science ®Google Scholar
• Erro R, Santangelo G, Barone P, et al. Do subjective memory complaints herald the onset of mild cognitive impairment in Parkinson disease? J Geriatr Psychiatry Neurol. 2014;27(4):276–281.
   PubMed Web of Science ®Google Scholar
• Manganelli F, Vitale C, Santangelo G, et al. Functional involvement of central cholinergic circuits and visual hallucinations in Parkinson’s disease. Brain. 2009;132(Pt 9):2350–2355.
   PubMed Web of Science ®Google Scholar
• Moccia M, Mollenhauer B, Erro R, Picillo M, Palladino R, Barone P. Non-Motor Correlates of Smoking Habits in de Novo Parkinson’s Disease. J Parkinsons Dis. 2015;5(4):913–924.
   Google Scholar
• Kotagal V, Albin RL, Müller ML, Koeppe RA, Frey KA, Bohnen NI. Modifiable cardiovascular risk factors and axial motor impairments in Parkinson disease. Neurology. 2014;82:1514–1520.
   Web of Science ®Google Scholar
• Costa A, Peppe A, Carlesimo GA et al. Brain-derived neurotrophic factor serum levels correlate with cognitive performance in Parkinson’s disease patients with mild cognitive impairment. Front Behav Neurosci. 2015;9:253.
   Web of Science ®Google Scholar
• Chen-Plotkin AS, Hu WT, Siderowf A et al. Plasma EGF levels predict cognitive decline in Parkinson’s disease. Ann Neurol. 2011;69(4):655–663.
   PubMed Web of Science ®Google Scholar
• Pellecchia MT, Santangelo G, Picillo M, et al. Serum epidermal growth factor predicts cognitive functions in early, drug-naive Parkinson’s disease patients. J Neurol. 2013;260(2):438–444.
   PubMed Web of Science ®Google Scholar
• Meamar R, Shaabani P, Tabibian SR, Aghaye Ghazvini MR, Feizi A. The effects of uric acid, serum vitamin D3, and their interaction on Parkinson’s disease severity. Parkinsons Dis. Epub 2015 Feb 24.
   Google Scholar
• Dufek M, Rektorova I, Thon V, Lokaj J, Rektor I. Interleukin-6 May Contribute to Mortality in Parkinson’s Disease Patients: A 4-Year Prospective Study. Parkinsons Dis. Epub 2015 Aug 16.
   Google Scholar
• Hofmann KW, Schuh AFS, Saute J, et al. Interleukin-6 serum levels in patients with Parkinson’s disease. Neurochem Res. 2009;34(8):1401–1404.
   Web of Science ®Google Scholar
• Tang P, Chong L, Li X, et al. Correlation between serum RANTES levels and the severity of Parkinson’s disease. Oxid Med Cell Longev. 2014;2014:208408.
   PubMed Web of Science ®Google Scholar
• Jiménez-Jiménez F, Molina J, de Bustos F, et al. Serum levels of coenzyme Q10 in patients with Parkinson’s disease. J Neural Transm. 2000;107:177–181.
   PubMed Web of Science ®Google Scholar
• Ascherio A, LeWitt P, Xu K, et al. Urate predicts rate of clinical decline in Parkinsons disease. Arch Neurol. 2009;66(12):1460–1468.
   PubMed Web of Science ®Google Scholar
• Zhang H, Guo J, He D, et al. Lower serum UA levels in Parkinson’s disease patients in the Chinese population. Neurosci Lett. 2012;514(2):152–155.
   Web of Science ®Google Scholar
• Jesús S, Pérez I, Cáceres-Redondo MT, et al. Low serum uric acid concentration in Parkinson’s disease in southern Spain. Eur J Neurol. 2013;20(1):208–210.
   Web of Science ®Google Scholar
• Pan M, Gao H, Long L et al. Serum uric acid in patients with Parkinson’s disease and vascular parkinsonism: a cross-sectional study. Neuroimmunomodulation. 2013;20(1):19–28.
   PubMed Web of Science ®Google Scholar
• Lolekha P, Wongwan P, Kulkantrakorn K. Association between serum uric acid and motor subtypes of Parkinson’s disease. J Clin Neurosci. 2015;22(8):1264–1267.
   Web of Science ®Google Scholar
• Fukae J, Ishikawa K, Hatano T, et al. Serum uric acid concentration is linked to wearing-off fluctuation in Japanese Parkinson’s disease patients. J Parkinsons Dis. 2014;4(3):499–505.
   Google Scholar
• Moccia M, Picillo M, Erro R, et al. Presence and progression of non-motor symptoms in relation to uric acid in de novo Parkinson’s disease. Eur J Neurol. 2015;22(1):93–98.
   Web of Science ®Google Scholar
• Moccia M, Picillo M, Erro R, et al. Is serum uric acid related to non-motor symptoms in de-novo Parkinson’s disease patients? Parkinsonism Relat Disord. 2014;20(7):772–775.
   Web of Science ®Google Scholar
• Annanmaki T, Pessala-Driver A, Hokkanen L, Murros K. Uric acid associates with cognition in Parkinson’s disease. Parkinsonism Relat Disord. 2008;14(7):576–578.
   Web of Science ®Google Scholar
• Annanmaki T, Pohja M, Parviainen T, Hakkinen P, Murros K. Uric acid and cognition in Parkinson’s disease: a follow-up study. Parkinsonism Relat Disord. 2011;17(5):333–337.
   Web of Science ®Google Scholar
• Schwarzschild MA, Ascherio A, Beal MF, et al. Inosine to increase serum and cerebrospinal fluid urate in Parkinson disease: a randomized clinical trial. JAMA Neurol. 2014;71(2):141–150.
   PubMed Web of Science ®Google Scholar
• Yu SY, Sun L, Liu Z, et al. Sleep disorders in Parkinson’s disease: clinical features, iron metabolism and related mechanism. PLoS One. 2013;8(12):e82924.
   PubMed Web of Science ®Google Scholar
• Hu Y, Yu SY, Zuo L-J, et al. Investigation on Abnormal Iron Metabolism and Related Inflammation in Parkinson Disease Patients with Probable RBD. PLoS One. 2015;10(10):e0138997.
   Web of Science ®Google Scholar
• Fukushima T, Tan X, Luo Y, et al. Heavy metals in blood and urine and its relation to depressive symptoms in Parkinson’s disease patients. Fukushima J Med Sci. 2013;59(2):76–80.
   Google Scholar
• van Dijk KD, Bidinosti M, Weiss A, Raijmakers P, Berendse HW, van de Berg WDJ. Reduced α-synuclein levels in cerebrospinal fluid in Parkinson’s disease are unrelated to clinical and imaging measures of disease severity. Eur J Neurol. 2014;21(3):388–394.
   PubMed Web of Science ®Google Scholar
• Hall S, Surova Y, Öhrfelt A, Zetterberg H, Lindqvist D, Hansson O. CSF biomarkers and clinical progression of Parkinson disease. Neurology. 2015;84:57–63.
   PubMed Web of Science ®Google Scholar
• Liu C, Cholerton B, Shi M, et al. CSF tau and tau/Aβ42 predict cognitive decline in Parkinson’s disease. Parkinsonism Relat. Disord. 2015;21:271–276.
   Web of Science ®Google Scholar
• Kang JH, Chen-Plotkin AS., Siderowf A. Association of cerebrospinal fluid β-amyoid 1-42, T-tau, P-tau181, and α-synuclein levels with clinical features of drug-naive patients with early Parkinson disease. JAMA Neurol. 2013;70(10):1277–1287.
   PubMed Web of Science ®Google Scholar
• OldeDubbelink KT, Schoonheim MM, Deijen JB, Twisk JW, Barkhof F, Berendse HW. Functional connectivity and cognitive decline over 3 years in Parkinson disease. Neurology. 2014;83(22):2046–2053.
   Web of Science ®Google Scholar
• Amboni M, Tessitore A, Esposito F, et al. Resting-state functional connectivity associated with mild cognitive impairment in Parkinson’s disease. J Neurol. 2015;262(2):425–434.
   PubMed Web of Science ®Google Scholar
• Tessitore A, Amboni M, Esposito F, et al. Resting-state brain connectivity in patients with Parkinson’s disease and freezing of gait. Parkinsonism Relat Disord. 2012;18(6):781–787.
   PubMed Web of Science ®Google Scholar
• Jia X, Liang P, Li Y, Shi L, Wang D, Li K. Longitudinal Study of Gray Matter Changes in Parkinson Disease. AJNR Am J Neuroradiol. 2015;36(12):2219–2226.
   Web of Science ®Google Scholar
• Ibarretxe-Bilbao N, Junque C, Segura B, et al. Progression of cortical thinning in early Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2013;84(8):875–881.
   Web of Science ®Google Scholar
• Zarei M, Ibarretxe-Bilbao N, Compta Y et al. Cortical thinning is associated with disease stages and dementia in Parkinson’s disease. Mov Disord. 2012;27(14):1746–1753.
   Web of Science ®Google Scholar
• Ulla M, Bonny JM, Ouchchane L, Rieu I, Claise B, Durif F. Is R2* a new MRI biomarker for the progression of Parkinson’s disease? A longitudinal follow-up. PLoS One. 2013;8(3):e57904.
   Google Scholar
• McKeown MJ, Peavy GM. Biomarkers in Parkinson disease: it’s time to combine. Neurology. 2015;84(24):2392–2393.
   PubMed Web of Science ®Google Scholar
• Campbell MC, Koller JM, Snyder AZ, Buddhala C, Kotzbauer PT, Perlmutter JS. CSF proteins and resting-state functional connectivity in Parkinson disease. Neurology. 2015;84(24):2413–2421.
   Web of Science ®Google Scholar
• Rosenthal LS, Drake D, Alcalay RN, et al. PDBP consortium. The NINDS Parkinson’s disease biomarkers program. Mov Disord. Epub 2015 Oct 7.
   Google Scholar